ADHD Drug Warnings In New Highlights Section Replaces Need For Black Box

The ability to highlight warnings under FDA's new labeling rule may obviate the need for a "black box" warning against risks associated with attention deficit/hyperactivity disorder drugs, FDA's Pediatric Advisory Committee suggested March 22